Bright Minds Biosciences (DRUG) Expected to Announce Earnings on Friday

Bright Minds Biosciences (NASDAQ:DRUG) is expected to be releasing its Q2 2026 results before the market opens on Friday, May 15th. Analysts expect Bright Minds Biosciences to post earnings of ($0.8686) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, May 22, 2026 at 4:00 PM ET.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its earnings results on Thursday, February 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.28. On average, analysts expect Bright Minds Biosciences to post $-5 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Bright Minds Biosciences Stock Performance

NASDAQ DRUG opened at $84.65 on Wednesday. The company has a market capitalization of $823.81 million, a P/E ratio of -43.86 and a beta of -5.35. Bright Minds Biosciences has a one year low of $23.17 and a one year high of $123.75. The stock has a 50 day moving average price of $80.48 and a 200-day moving average price of $77.40.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DRUG. BTIG Research reiterated a “buy” rating and set a $147.00 target price on shares of Bright Minds Biosciences in a research report on Monday, March 30th. Robert W. Baird set a $126.00 price target on Bright Minds Biosciences in a research report on Friday, February 13th. Wall Street Zen downgraded Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. HC Wainwright raised their price target on Bright Minds Biosciences from $115.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Jefferies Financial Group began coverage on Bright Minds Biosciences in a research report on Monday, April 13th. They issued a “buy” rating and a $145.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.60.

Insiders Place Their Bets

In other Bright Minds Biosciences news, major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $89.50, for a total value of $9,785,124.50. Following the sale, the insider owned 950,000 shares in the company, valued at $85,025,000. This trade represents a 10.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 42.66% of the stock is currently owned by insiders.

Institutional Trading of Bright Minds Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of DRUG. Vivo Capital LLC increased its stake in shares of Bright Minds Biosciences by 99.4% during the third quarter. Vivo Capital LLC now owns 501,617 shares of the company’s stock valued at $30,428,000 after buying an additional 250,045 shares during the period. MPM Bioimpact LLC purchased a new position in shares of Bright Minds Biosciences during the fourth quarter valued at $17,961,000. Balyasny Asset Management L.P. purchased a new position in shares of Bright Minds Biosciences during the third quarter valued at $11,339,000. Millennium Management LLC increased its stake in shares of Bright Minds Biosciences by 376.9% during the first quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock valued at $6,946,000 after buying an additional 152,178 shares during the period. Finally, Ikarian Capital LLC increased its stake in shares of Bright Minds Biosciences by 933.1% during the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company’s stock valued at $12,441,000 after buying an additional 143,990 shares during the period. Hedge funds and other institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.